KL (6431) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 光麗-KY

KL (6431) reported revenue of NT$41.4 million for Oct 2026, +53.0% year on year and -23.4% from the previous month. Revenue for Jan–Oct 2026 was NT$357.9 million (+20.7% year on year).

Year-on-year revenue growth: 5 months in a row. →

In Oct 2026, it ranked No. 106 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$52.9 million24/10Nov 2024 NT$29 millionDec 2024 NT$41 millionJan 2025 NT$45.1 millionFeb 2025 NT$26 million25/02Mar 2025 NT$38.3 millionApr 2025 NT$31.8 millionMay 2025 NT$36.2 millionJun 2025 NT$21.8 million25/06Jul 2025 NT$17.7 millionAug 2025 NT$14.7 millionSep 2025 NT$37.8 millionOct 2025 NT$27.1 million25/10Nov 2025 NT$44.8 millionDec 2025 NT$41 millionJan 2026 NT$37.5 millionFeb 2026 NT$21.9 million26/02Mar 2026 NT$26 millionApr 2026 NT$41.7 millionMay 2026 NT$27.8 millionJun 2026 NT$29.9 million26/06Jul 2026 NT$35.7 millionAug 2026 NT$41.9 millionSep 2026 NT$54 millionOct 2026 NT$41.4 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$41.4 million+53.0%-23.4%
Sep 2026NT$54 million+42.9%+29.0%
Aug 2026NT$41.9 million+185.9%+17.2%
Jul 2026NT$35.7 million+101.7%+19.5%
Jun 2026NT$29.9 million+37.1%+7.7%
May 2026NT$27.8 million-23.2%-33.4%
Apr 2026NT$41.7 million+31.2%+60.4%
Mar 2026NT$26 million-32.1%+18.4%
Feb 2026NT$21.9 million-15.6%-41.5%
Jan 2026NT$37.5 million-16.8%-8.5%
Dec 2025NT$41 million+0.0%-8.5%
Nov 2025NT$44.8 million+54.3%+65.5%
Oct 2025NT$27.1 million-48.9%-28.5%
Sep 2025NT$37.8 million+8.7%+158.1%
Aug 2025NT$14.7 million-68.2%-17.3%
Jul 2025NT$17.7 million-23.3%-18.8%
Jun 2025NT$21.8 million-10.2%-39.7%
May 2025NT$36.2 million+42.1%+13.9%
Apr 2025NT$31.8 million-20.4%-17.0%
Mar 2025NT$38.3 million+30.6%+47.4%
Feb 2025NT$26 million+167.0%-42.3%
Jan 2025NT$45.1 million+94.0%+10.0%
Dec 2024NT$41 million+151.1%+41.3%
Nov 2024NT$29 million+8.9%-45.2%
Oct 2024NT$52.9 million+58.3%+52.0%

Jan–Oct 2026 cumulative: NT$357.9 million (+20.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: KL vs PEC / KL vs Lotus Pharm / KL vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

本年有新增子公司,故營業收入較去年同期 增加。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16